Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
Figure 5
Predicted % infections prevented by distinct TDF-based prophylactic strategies for various parameter sets.
A: Predicted % infections prevented by once daily 300 mg TDF taken at different levels of adherence and with distinct virus inoculum sizes. prophylactic efficacy depends on adherence at the p
0.05 or p
0.01 level respectively. B: Predicted % infections prevented by a one week 300 mg TDF (1w-PrEP/PEP) when started at distinct times before/after exposure with distinct numbers of viruses.
prophylactic efficacy depends on the timing of start of TDF administration at the p
0.05 or p
0.01 level respectively. C: Predicted % infections prevented by a single dose 300 mg TDF (sd-PrEP) when taken at distinct times before exposure with distinct virus inoculum sizes.
prophylactic efficacy depends on the timing of TDF single dose administration at the p
0.05 or p
0.01 level respectively. D: Predicted % infections prevented by a single dose 600 mg TDF (sd-PrEP) when taken at distinct times before exposure with distinct virus inoculum sizes. Error bars represent confidence bounds calculated using Greenwood’s formula.
prophylactic efficacy depends on the inoculum size. The predicted probability of infection in the absence of drugs
was
,
,
and
when
= 1, 5, 20 or 100, respectively, viruses were inoculated.